Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist.
CONCLUSIONS: Based on available data, ubrogepant, rimegepant, and lasmiditan should be reserved as second-line therapy and may be safe in patients with cardiovascular risk. Lasmiditan's adverse effect profile may limit its use.
PMID: 32993366 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Joyner KR, Morgan KW Tags: Ann Pharmacother Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Genetics | Headache | Heart | Migraine | Pain | Pain Management | Study